Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Toyama licenses neuroprotective compound from Senju

Oct. 22, 1998

Lomerizine, a new antimigraine agent, compared to flunarizine in rats

Oct. 22, 1998

Dopaminergic and serotonergic agents synthesized at Lundbeck

Oct. 22, 1998

NOS inhibitors developed at Chugai reportedly useful for cerebrovascular disorders

Oct. 22, 1998

Pramipexole improves rest tremor in Parkinson's disease

Oct. 22, 1998

Linopirdine analogue proves to be more potent neurotransmitter release enhancer

Oct. 21, 1998

Versed Syrup approved for pediatric sedation

Oct. 21, 1998

MorphiDex NDA accepted for FDA review

Oct. 21, 1998

Potent CRF1 receptor antagonists and their use described by Yoshitomi

Oct. 21, 1998

Phase I trial for Anergen multiple sclerosis compound demonstrates safety

Oct. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.